Document Detail


Renal and vascular protective effects of telmisartan in patients with essential hypertension.
MedLine Citation:
PMID:  17137211     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is known that the angiotensin receptor blockers (ARBs) have organ protective effects in patients with heart failure or renal impairment. Several studies have revealed that the ARB telmisartan has an organ protective effect, but there have been few studies directly comparing the effects of telmisartan and calcium antagonists, since most clinical studies on telmisartan have been conducted in treated patients or patients on combination therapy. The present study was conducted to compare the renal and vascular protective effects of telmisartan monotherapy and calcium antagonist monotherapy in untreated hypertensive patients. Forty-three patients with untreated essential hypertension were randomized to receive amlodipine (n=22) or telmisartan (n=21), which were respectively administered at doses of 5 mg and 40 mg once daily in the morning for 24 weeks. The patients were examined before and after treatment to assess changes of renal function, flow-mediated dilation (a parameter of vascular endothelial function), and brachial-ankle pulse wave velocity (baPWV; a parameter of arteriosclerosis). Before treatment, there were no significant differences in these parameters between groups. The decreases of urinary albumin excretion and baPWV, and the increase of flow-mediated dilation were significantly greater in the telmisartan group than the amlodipine group, while the antihypertensive effects were not significantly different between the two groups. In conclusion, these results suggest that telmisartan is more effective at protecting renal function and vascular endothelial function, and at improving arteriosclerosis than the calcium channel blocker in patients with essential hypertension.
Authors:
Satoshi Morimoto; Yutaka Yano; Kei Maki; Katsunori Sawada
Publication Detail:
Type:  In Vitro; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  29     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-12-01     Completed Date:  2007-01-11     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  567-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / pharmacology*,  therapeutic use
Angiotensin II Type 1 Receptor Blockers / pharmacology*,  therapeutic use
Arteriosclerosis / drug therapy
Benzimidazoles / pharmacology*,  therapeutic use
Benzoates / pharmacology*,  therapeutic use
Blood Pressure / drug effects
Calcium Channel Blockers / pharmacology*,  therapeutic use
Endothelium, Vascular / drug effects*
Female
Heart Rate / drug effects
Humans
Hypertension / drug therapy
Kidney / drug effects*
Male
Middle Aged
Vasodilation / drug effects
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Calcium Channel Blockers; 1J444QC288/Amlodipine; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impairment of instantaneous autonomic regulation relates to blood pressure fall immediately after st...
Next Document:  Synthetic/secreting and apoptotic phenotypes in renal biopsy tissues from hypertensive nephroscleros...